As established brands face increasing pressure from loss of exclusivity, pricing constraints, and shifting market dynamics, many organizations are rethinking how these portfolios are managed and monetized.

In this session, we’ll explore how leading pharma companies are reshaping commercial operating models—leveraging data, AI, and flexible commercialization approaches to drive greater agility across in-market brands.

Register now to learn how to turn established brands into a high-performing, strategically managed portfolio—supporting both near-term performance and long-term growth ambitions.